Paris - Delayed Quote EUR

AB Science S.A. (AB.PA)

Compare
1.6480
+0.0160
+(0.98%)
As of 10:33:41 AM GMT+1. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for AB.PA

Recent News: AB.PA

View More
AB Science provides a summary of the webcast held on December 16, 2024

AB Science provides a summary of the webcast held on December 16, 2024
GlobeNewswire 27 days ago
AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET

AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET
GlobeNewswire last month
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
GlobeNewswire 2 months ago
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
GlobeNewswire 2 months ago
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
GlobeNewswire 3 months ago
AB Science announces a slight delay in the publication of its 2024 half-year financial report

AB Science announces a slight delay in the publication of its 2024 half-year financial report
GlobeNewswire 3 months ago
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement

AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
GlobeNewswire 3 months ago
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
GlobeNewswire 3 months ago
AB Science touts positive Phase II Covid-19 data for masitinib

AB Science touts positive Phase II Covid-19 data for masitinib
Clinical Trials Arena 6 months ago
AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19

AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
GlobeNewswire 6 months ago
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
GlobeNewswire 7 months ago
View More

Related Tickers

BXT.DE BioNxt Solutions Inc.
0.2840
+1.07%
 
CYTH Cyclo Therapeutics, Inc.
0.6601
+4.45%
 
29A.SG Amphastar Pharmaceuticals Inc
36.19
-0.74%
 
0ET.MU Esperion Therapeutics Inc
2.1980
0.00%
 
068760.KQ Celltrion Pharm, Inc.
55,900.00
-0.71%
 
ARSUF Fagron NV
20.03
0.00%
 
SPBBF Speakeasy Cannabis Club Ltd.
0.0000
0.00%
 
R9U2.F Green Thumb Industries Inc.
7.00
-0.64%
 
EVT.VI Evotec SE
8.17
+1.49%
 
MB8.F Moberg Pharma AB (publ)
0.7550
-0.66%